enVVeno Medical logo

enVVeno MedicalNASDAQ: NVNO

Profile

Sector:

Healthcare

Country:

United States

IPO:

31 May 2018

Next earnings report:

28 February 2025

Last dividends:

N/A

Next dividends:

N/A
$61.55 M
-33%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector
-55%vs. 3y high
45%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 22:59:47 GMT
$3.51-$0.18(-4.88%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

NVNO Latest News

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
accesswire.com20 November 2024 Sentiment: POSITIVE

85% Clinical Meaningful Benefit Responder Rate 7.91 Point Average rVCSS Improvement for the Clinically Meaningful Benefit Responder Cohort 75% Median Reduction in Pain (VAS) 87% Median Ulcer Area Reduction 97% Target Vein Patency Rate Improvement in All Patient Reported Quality-of-Life Indicators Company to Host Video Conference Call with VEITH Presenters Today at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 20, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical seeking pre-market authorization (PMA) from the U.S. Food and Drug Administration (FDA) to market and sell the VenoValve in the U.S. Among the data being presented at VEITH are: Eighty five percent (85%) of the subjects in the VenoValve pivotal study that reached the one-year milestone achieved a clinically meaningful benefit of a three (3) or more point improvement in revised Venous Clinical Severity Score (rVCSS).

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
accesswire.com19 November 2024 Sentiment: POSITIVE

Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium Company to Host a Conference Call with the PIs Presenting the Pivotal Trial Data on Wednesday, November 20th at 2:00 PM Eastern Time - Click Here to Access IRVINE, CA / ACCESSWIRE / November 19, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the FDA.

What type of business is enVVeno Medical?

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

What sector is enVVeno Medical in?

enVVeno Medical is in the Healthcare sector

What industry is enVVeno Medical in?

enVVeno Medical is in the Medical Devices industry

What country is enVVeno Medical from?

enVVeno Medical is headquartered in United States

When did enVVeno Medical go public?

enVVeno Medical initial public offering (IPO) was on 31 May 2018

What is enVVeno Medical website?

https://www.envveno.com

Is enVVeno Medical in the S&P 500?

No, enVVeno Medical is not included in the S&P 500 index

Is enVVeno Medical in the NASDAQ 100?

No, enVVeno Medical is not included in the NASDAQ 100 index

Is enVVeno Medical in the Dow Jones?

No, enVVeno Medical is not included in the Dow Jones index

When was enVVeno Medical the previous earnings report?

No data

When does enVVeno Medical earnings report?

The next expected earnings date for enVVeno Medical is 28 February 2025